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Dissemination of pseudomyxoma peritonei into the thoracic cavity is rare and carries a poor 
prognosis. Optimal treatment has not been defined. In our institution, patients had received 
cytoreductive surgery with hyperthermic intrathoracic chemotherapy, which demonstrated good 
prognosis. A 51-year-old woman was referred to our hospital with right intrathoracic 
dissemination of pseudomyxoma peritonei. We performed parietal and mediastinal pleurectomy 
and simple resection of all visible tumors on the diaphragm and visceral pleura, followed by 
hyperthermic intrathoracic chemotherapy with 20 mg itomycin at 42–43ºC. The patient had no 










Pseudomyxoma peritonei (PMP) is a rare disease, with an estimated incidence of two cases per 
million people per year[1]. PMP is caused by the dissemination of a mucin-producing tumor, 
characterized by the accumulation of mucinous ascite  in the peritoneal cavity. Although the 
optimal treatment for PMP has not been adequately defined, aggressive cytoreductive surgery 
with intraperitoneal chemotherapy (HIPEC) has demonstrated prolonged survival or even a 
complete cure[2]. Extension of PMP into the thoracic cavity is extremely rare and carries a poor 
prognosis[1]. Although systemic palliative chemotherapy remains the usual treatment option, 
only one report has demonstrated that cytoreductive surgery with hyperthermic intrathoracic 
chemotherapy (HITHOC) prolonged the 5-year survival rate by 46.1% in patients with 
intrathoracic PMP[3].   
Because intrathoracic dissemination of PMP is extremely rare and cytoreductive surgery with 
HITHOC may be performed in our institution only, and sixteen patients received the treatment 
between January 2010 and December 2019, we introduced the method for the first time. 
 
Technique 
Institutional review board approval was obtained for this study (Approval Number: 
2018-0704-10). 
We had previously reported surgical outcome of intrathoracic PMP in patients received 
treatment between January 2010 and June 2018[3]. After we had reported, we continued 
cytoreductive surgery with hyperthermic intrathoracic chemotherapy for patients with 
intrathoracic dissemination of PMP. We showed a typical case of our treatment with a figure and 
video, which performed after the report. A 51-year-old asymptomatic woman was referred to 
our hospital because of a suspected right intrathorcic dissemination of PMP based on an 
imaging test. Computed tomography revealed diffuse masses along with pleura (Fig 1A), and 
magnetic resonance imaging reveals high intensity T2 masses (Fig 1B). The patient had 
undergone cytoreductive surgery and HIPEC for peritoneal dissemination of PMP 3 years ago, 
and there had been no evidence of recurrences in the abdominal cavity. Thoracoscope under 
local anesthesia revealed multiple masses on the pari tal and visceral pleura (Fig 2A), and 
biopsy confirmed diagnosis of intrathoracic PMP.  
 Under general anesthesia, ventilation was provided to the left lung using a double-lumen 
endotracheal tube. The patient was placed in a left lateral position on the operating table. We 
performed cytoreductive surgery and macroscopic complete resection of all intrathoracic tumors. 
A posterolateral incision of approximately 25 cm was made and the 7th intercostal muscle was 
resected. Between the 7th intercostal space, parietal pleura was detached from the chest wall 
using the surgeon’s finger; the mediastinal pleura w s also detached. The parietal and 
mediastinal pleura with tumors were thus removed from the thoracic cavity. Visible tumors on 
the diaphragm were resected with electrocauterization and the diaphragm was partially resected 
with tumors. Visible tumors on the visceral pleura were cut off with scissors, and if the tumor 
adhered strongly to the lung, we performed partial esection of the lung using an Endo GIA 
tri-stapler (Covidien). Damaged visceral pleurae were r paired with 4-0 PDS*Ⅱ (Ethicon) and 
damaged diaphragm with 3-0 PDS*Ⅱ (Ethicon). We confirmed no air leaks with a sealing test, 
performed under bilateral ventilation at 15 cmH2O of maximum intrabronchial pressure. 
Following complete cytoreductive surgery (Fig 2B), the patient was administered HITHOC. 
Saline and anticancer therapy with 20 mg mitomycin at 42–43ºC were administered. We 
positioned two intrathoracic drains; one inflow from the midaxillary line at the 7th intercostal 
space to the apical portion, and one outflow from the posterior axillary line at the 9th intercostal 
space to the supradiaphragmatic portion. The medications were then circulated for one hour.  
 Patients were discharged from our hospital on postoperative day 11 without complications and 
had no evidence of disease progression in the thoracic c vity 1 year after surgery. 
 
Comment 
PMP has been regarded as an incurable disease for a long time and, if untreated, is usually fatal. 
There was no evidence of the efficacy of systemic chemotherapy or radiation therapy for PMP. 
Recently, some reports have shown that cytoreductive surgery, macroscopic complete resection 
of visible peritoneal lesions, and HIPEC provided the possibility of a cure or at least an 
increased survival time[4].  
 Extension of PMP to the thoracic cavity through the diaphragm is extremely rare (5.4%)[1]. 
Thoracic dissemination will cause restrictive ventilatory impairment due to accumulation of 
mucinous fluid in the thoracic cavity. In such cases, arly treatment is needed for patients. In 
contrast, most patients with intrathoracic disseminations received only palliative care because 1) 
lack of studies has been a major challenge in the management of this extremely rare disease, 2) 
treatments are thought to be associated with high morbidity and mortality, and 3) these patients 
are expected to have a poor prognosis. However, we beli ved that cytoreductive surgery and 
HITOC might contribute to a better prognosis, such as in abdominal PMP. We previously 
reported that long-term patient survival can be expected, with a 5-year survival rate of 46.1%, 
with intrathoracic cytoreductive surgery followed by HITHOC for disseminated PMP with 
feasible complications[3]. It is essential for us to communicate the method used to treat this rare 
disease to other institutions.  
The goal of cytoreductive surgery was complete macroscopic resection of the tumors. To 
achieve this goal, we first performed parietal and mediastinal pleurectomies because most 
tumors adhered to the parietal and mediastinal pleurae. Next, we performed simple resection of 
all visible tumors on the diaphragm and visceral pleura. During simple resection, sufficient 
margin between tumors and adjacent organs is not necessary because following HITHOC 
microscopic, residual tumors are expected to be eliminated. Yonemura, et al reported that 
anticancer drugs penetrate 2 mm into the adjacent tissues by HITHOC[5]. 
 If possible, we should set a goal of microscopic complete resection by extrapleural 
pneumonectomy or pleurectomy decortication. However, microscopic complete resection of 
PMP is challenging because it is easy for mucus, which includes tumor cells, to drop into the 
thoracic cavity during surgery, facilitating the development of local recurrences. Furthermore, 
extrapleural pneumonectomy or pleurectomy decortication are more invasive than our 
cytoreductive surgery. Patients who had received abdominal cytoreductive surgery or systemic 
chemotherapy often have poor physical capacities and thus we should avoid invasive surgery. 
Therefore, cytoreductive surgery following HITHOC may be a feasible treatment for managing 
this disease. 
 In conclusion, the cytoreductive surgery and HITHOC approach described here might 
constitute an optimized method to treat intrathoracic dissemination of PMP. We hope that, in the 
future, patients with this condition in various inst tutions can receive the survival benefits 
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Fig 1. (A) Computed tomography shows diffuse masses along the pleura. (B) Magnetic 
resonance imaging reveals high intensity T2 masses. 
 
Fig 2. (A) Thoracoscope under local anesthesia show multiple masses on the parietal and 
visceral pleura. (B) Visible tumors in the thoracic avity completely resected by cytoreductive 
surgery. 
 


